Navigation Links
Oncolytics Biotech Inc. Announces Publication of Research on Immune Response to REOLYSIN(R) during a Phase I Clinical Trial
Date:3/17/2008

CALGARY, March 17 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) ('Oncolytics') reported today that Dr. Kevin Harrington and his research group at The Institute of Cancer Research, London, U.K. published the results of their work characterizing immune system responses to administration of intravenous REOLYSIN(R) in a Phase I clinical trial. The paper, entitled "Characterization of the Adaptive and Innate Immune Response to Intravenous Oncolytic Reovirus (Dearing Type 3) during a Phase I Clinical Trial" appears online in the March 6, 2008 issue of Gene Therapy.

"This important work further defines the relationship between viral therapy and human immune response, and supports the development of our ongoing Phase II clinical trial program," said Dr. Brad Thompson, President and CEO of Oncolytics.

The investigators conducted a detailed analysis of the immune effects of intravenous viral therapy by collecting and analyzing immune response to the presence of the virus. The results suggest that reovirus may stimulate the immune system to mount a dynamic immune response to the presence of virus, increasing the potential to significantly enhance the efficacy of oncolytic virotherapy. About a third of those patients also showed increases in NK (natural killer) cells following therapy. The data support the development of interventions aimed at blunting the patient's immune response, although preclinical data also suggest that maintaining a baseline level is necessary to restrict systemic spread/toxicity of the virus.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information abo
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Oncolytics Biotech Inc. Collaborators to Present Reovirus Research at AACR Annual Meeting
2. Media Advisory - Oncolytics Biotech Inc. to Present at BioSquare 2008
3. Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007
4. Media Advisory - Oncolytics Biotech Inc. to Present at Bio CEO & Investor Conference
5. Oncolytics Biotech Inc. Announces Publication of Research on Combination Reovirus and Radiation Therapy
6. Oncolytics Biotech Inc. Proceeds to Full Enrolment in U.S. Phase II Sarcoma Clinical Trial
7. Oncolytics Biotech Inc. Announces Issuance of 8th Canadian Patent
8. Oncolytics Biotech Inc. Announces Publication of Research on Combination Reovirus and Cyclophosphamide Treatment
9. Oncolytics Biotech Inc. Announces Filing of Phase 1/2 Clinical Trial with REOLYSIN(R)
10. Oncolytics Biotech Inc. Completes Patient Enrolment in U.K. Phase Ia/Ib Combination REOLYSIN(R)/Radiation Clinical Trial
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... 28, 2015 RXi Pharmaceuticals Corporation (NASDAQ: ... developing innovative therapeutics, primarily in the areas of dermatology ... offering of 26 million units at a price to ... of approximately $10.4 million. Each unit consists of (i) ... purchase right to purchase 0.50 of a share of ...
(Date:5/28/2015)... York and London (PRWEB) May 28, 2015 ... provider of Computer Aided Engineering software, announced today ... Research, Inc. (PSRI). CD-adapco will provide state-of-the-art engineering ... members will share their expertise and experiences in ... and refining industry members and advance the understanding ...
(Date:5/28/2015)... York, NY (PRWEB) May 28, 2015 ... renewed and enhanced its long term partnership with PTI ... work together to provide clients with custom-tailored method ... the art instruments currently available. The agreement includes a ... companies’ employees across organizational lines. This enables a ...
(Date:5/28/2015)... 2015 Dr. Carl Peck, MD, ... Roger L. Williams, MD, has joined the firm ... Experts are top tier consultants whose expertise and ... to the company’s clients. Premier Experts collaborate to ... successfully develop their medical products, pursue optimal regulatory ...
Breaking Biology Technology:RXi Pharmaceuticals Announces $10 Million Public Offering of Common Stock and Warrants 2RXi Pharmaceuticals Announces $10 Million Public Offering of Common Stock and Warrants 3CD-adapco and PSRI Chartering New Course in Particle Flow Simulations 2Whitehouse Labs Renews & Enhances Partnership with PTI Inspection Systems 2Whitehouse Labs Renews & Enhances Partnership with PTI Inspection Systems 3Former CEO and Chair of the Council of Experts at the USP, Roger L. Williams, MD, Joins NDA Partners as a Premier Expert Consultant 2
... Oct. 21 /PRNewswire-FirstCall/ - SemBioSys Genetics Inc. ("SemBioSys") ... entered into a definitive agreement to acquire all ... Specialty Ingredients Inc. ("Botaneco") held by SemBioSys and ... an initial 9.48 percent shareholding in Advitech, in ...
... BEIJING, Oct. 20, 2009 Monsanto Company and Huazhong ... the development of novel traits such as higher yield, ... and advance certain technologies developed by Professor Qifa Zhang,s ... "We,re excited to be working with a prominent research ...
... 20 NuVasive, Inc. (Nasdaq: NUVA ... minimally disruptive surgical treatments for the spine, announced today financial ... reported third quarter revenue of $94.9 million, a 41.8% increase ... a 7.3% increase over the $88.5 million for the second ...
Cached Biology Technology:SemBioSys provides an update on Botaneco 2SemBioSys provides an update on Botaneco 3SemBioSys provides an update on Botaneco 4Monsanto and Huazhong Agricultural University Enter Into Collaboration Focusing on Development of Plant Biotechnology 2Monsanto and Huazhong Agricultural University Enter Into Collaboration Focusing on Development of Plant Biotechnology 3NuVasive Reports Third Quarter 2009 Financial Results 2NuVasive Reports Third Quarter 2009 Financial Results 3NuVasive Reports Third Quarter 2009 Financial Results 4NuVasive Reports Third Quarter 2009 Financial Results 5NuVasive Reports Third Quarter 2009 Financial Results 6NuVasive Reports Third Quarter 2009 Financial Results 7NuVasive Reports Third Quarter 2009 Financial Results 8NuVasive Reports Third Quarter 2009 Financial Results 9NuVasive Reports Third Quarter 2009 Financial Results 10NuVasive Reports Third Quarter 2009 Financial Results 11NuVasive Reports Third Quarter 2009 Financial Results 12
(Date:5/18/2015)... GOTHENBURG, Sweden , May 18, 2015 ... touch fingerprint sensors FPC1020, FPC1025, FPC1145, FPC1155 and FPC1035 from ... place from June until and including Q3 2015 and the ... Asia . Communicated order values for 2015 hereby amount ... revenues for Q1 2015 of 140 MSEK and a number ...
(Date:5/11/2015)... JOSE, Calif. , May 11, 2015 /PRNewswire/ ... developer of human interface solutions, today announced the ... Vice President and Chief Financial Officer, reporting to ... Ali replaces Synaptics, current Chief Financial Officer, ... December 2014. Mr. Ali brings ...
(Date:5/10/2015)... Fingerprint Cards (FPC) has received an order for ... World Peace Industrial Group (WPI), part of WPG Holdings. WPI ... . Deliveries are planned to take place during Q3 2015 ... China . The order value of 235 ... 1 000 MSEK for 2015.   Jörgen Lantto, acting ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 235 Million 2
... release is available in German . , ... the 2009 Charles Rodolphe Brupbacher Prize for Cancer Research. Nubia ... tumours such as cervical cancer through human papilloma viruses and ... smoking. The prize from the Charles Rodolphe Brupbacher Foundation has ...
... available in German . The use of ... risk that people may come into contact with it, and ... risk. However, radioactivity is not the only problem related to ... more dangerous to human health. Researchers are still looking for ...
... 2009 An international conference that will explore Darwin,s ... May 25-29. It is being organized to coincide with ... the Origin of Species, (and the 200th anniversaryspecifically, todayof ... of biology," says Ralph Pudritz, director of McMaster,s Origins ...
Cached Biology News:Brupbacher prize to Nubia Munoz and Sir Richard Peto 2Brupbacher prize to Nubia Munoz and Sir Richard Peto 3A pocketful of uranium 2
... the consumable measurement plate for ... individually controlled measurement sites. Each ... liquid flow channel system that ... solution and compound applications necessary ...
... capable of dynamic scheduling, is designed to ... automation workcells easy for lab personnel, yet ... • Users create methods by ... can build a flowchart, you can write ...
... research demands continue to grow, the need ... information has become necessary, especially when discerning ... The innovative C1si Confocal Microscope System gives ... spectral capability not available in conventional confocal ...
... provides complete components including positive and ... of DNA fragmentation in cultured cells ... BrdU in the procedure provides greater ... Results can be analyzed by fluorescence ...
Biology Products: